Results 41 to 50 of about 48,011 (239)
Summary: The ex vivo production of platelets depleted of human leukocyte antigen class I (HLA-I) could serve as a universal measure to overcome platelet transfusion refractoriness caused by HLA-I incompatibility.
Daisuke Suzuki +16 more
doaj +1 more source
Glanzmannʼs Trombasthenia (GT) is a genetic disorder, that develops with a tendency toward bleeding and is characterized by the absence or decrease in platelet aggregation. Surgical bleeding may be difficult to control.
Flora Margarida Barra Bisinotto +3 more
doaj +1 more source
Background At our institution, patients with platelet refractoriness (of any etiology) are sometimes switched from apheresis platelets to pooled platelets before human leukocyte antigen (HLA)-matched units become available. Study design and methods Seven
Ying-Hsia Chu +3 more
doaj +1 more source
Platelet transfusion support is extensively required for hemato-oncology patients who are multiply transfused. Platelet refractoriness can represent a significant clinical condition that complicates the platelet transfusion support in such patients.
B Sunil Rajadhyaksha +2 more
doaj +1 more source
Background and Aims Platelet transfusion refractoriness is well aware to be associated with poor clinical outcomes. Patients with the alloantibody causing refractoriness required cross‐matched compatible products to improve the platelet number.
Thunnakhon Sinwatcharaphirom +2 more
doaj +1 more source
Transfusion effect of 0.5-dose of apheresis platelet in pediatric patients
Objective To investigate the transfusion effect of 0.5-dose of apheresis platelet in pediatric patients. Methods A total of 195 children who underwent 0.5-dose platelet transfusion from August 2021 to June 2022 were enrolled, and the platelet count ...
Lijuan QIU +3 more
doaj +1 more source
Prevention and Management of Platelet Transfusion Refractoriness [PDF]
AbstractPlatelet transfusion refractoriness is a major complication of long‐term platelet supportive care. Refractoriness may lead to fatal bleeding complications in thrombocytopenic patients. Major factors involved are factors related to the clinical condition of the patient as well as HLA alloimmunisation. Non‐alloimmune factors may occur in up to 80%
openaire +2 more sources
Platelet transfusions have contributed to the revolutionary modern treatment of hypoproliferative thrombocytopenia. Despite the long-term application of platelet transfusion in therapeutics, all aspects of their optimal use (i.e., in cases of ABO and/or ...
Serena Valsami +4 more
doaj +1 more source
Management of patients refractory to platelet transfusion [PDF]
Abstract Objective.—To present a current assessment and practical approach to the diagnosis and management of patients who are refractory to platelet transfusions. Design.—A task force was convened by the College of American Pathologists under the auspices of the Transfusion Medicine Resource Committee for the purposes of outlining current concepts in ...
openaire +2 more sources
Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness
Despite significant advancements in the production of platelet products, storage, and transfusion, transfusion refractoriness remains a significant clinical problem, affecting up to 14% of hematological patients receiving platelet transfusions.
Anno Saris +3 more
core +1 more source

